A pioneering antibiotic against toxic bacteria enters clinical trials
Escherichia coli (E. coli), a diverse group of bacteria normally found in the intestines, are mostly harmless while some are gut-friendly and beneficial to our health. However, among them, Shiga toxin-producing E. coli (STEC) are most commonly linked to foodborne outbreaks. Currently, treatment addresses only symptoms but not the cause of the illness. This may soon change thanks to the EU-funded SPELITEC programme as preclinical and clinical trials of a potent STEC eliminator will soon be underway. The drug stop STEC in its tracks without the release of the toxin into the intestines. Even better, it does not affect normal intestinal microorganisms or induce antibiotic resistance.
Fields of science
Call for proposalSee other projects for this call